Regulation of antibody immunotherapy by fine-tuning FcR interactions

Video   Apr 22, 2013


About the Speaker

Mark Cragg is a Professor in Experimental Cancer Biology at the Cancer Sciences Division of Southampton University School of Medicine, UK. He obtained his PhD in 1998 and did his postdoctoral studies with Martin Glennie in Southampton and then Andreas Strasser at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. He has published over 60 papers, many in high impact journals such as the Journal of Clinical Investigation, PNAS, Plos Medicine and Blood and leads a dynamic research group interested in all aspects of how therapeutics such as antibodies result in tumour regression and how they can be improved.

Monoclonal antibodies (mAb) represent a growing class of ‘block-buster’ cancer drugs and so understanding of their modes of action is critical. Here, we present evidence that different mAb interact with Fc receptors differently in order to achieve their therapeutic activities.


Recommended Videos

CAR T-Cell Therapy: How Does It Work?


CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system’s inherent cancer-fighting powers. It involves treating patients with modified versions of their own immune system T cells.


How Does Cancer Immunotherapy Work?


Traditionally, cancer treatment has revolved around chemotherapy, radiation and surgery. But thanks to groundbreaking immune checkpoint blockade research led by Jim Allison, Ph.D., we have a new way to treat cancer: immunotherapy. Rather than treating the cancer directly, immunotherapy trains the immune system to attack cancer.


PerkinElmer VICTOR Nivo Multimode Plate Reader - So Much Science So Little Bench Space


The VICTOR Nivo system: The next big thing in plate readers is now the smallest.



Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free